File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days

TitleA pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 days
Authors
KeywordsFirst trimester medical abortions
Letrozole
Mifepristone
Misoprostol
Issue Date2011
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/contraception
Citation
Contraception, 2011, v. 83 n. 1, p. 62-67 How to Cite?
AbstractBackground: Letrozole is a third-generation selective aromatase inhibitor. Animal data suggested that it might be useful in medical abortion. We performed two pilot studies to assess the feasibility of using letrozole in combination with either mifepristone or misoprostol for termination of pregnancy up to 63 days. Study Design: We recruited 40 subjects who requested legal termination of pregnancies up to 63 days. Medical abortion was performed with letrozole 7.5 mg daily for 2 days followed by 800 mcg vaginal misoprostol in 20 subjects and letrozole 7.5 mg combined with 200 mg mifepristone in another 20 subjects. Results: The mean induction-to-abortion interval of the regimen of letrozole and misoprostol was 9.1 h (median 7.9 h, range 2.7-23.6 h). The complete abortion rate was 80% (95% CI: 56.3-94.3%). For those with gestation of ≤49 days, the complete abortion rate was 87.5% (14/16; 95% CI: 61.7-98.5%). The mean induction-to-abortion interval of letrozole combined with mifepristone was 90.1 h (median 93.4 h, range 66.0-121.2 h). The complete abortion rate was 71.4% (95% CI: 47.8-88.7%). Conclusion: These preliminary results suggest that a regimen of letrozole and misoprostol may be useful in medical abortion, but the combination with mifepristone is less effective and takes longer. Randomized studies comparing letrozole and misoprostol to misoprostol alone are warranted. © 2011 Elsevier Inc. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/139909
ISSN
2015 Impact Factor: 2.788
2015 SCImago Journal Rankings: 1.557
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLee, VCYen_HK
dc.contributor.authorTang, OSen_HK
dc.contributor.authorNg, EHYen_HK
dc.contributor.authorYeung, WSBen_HK
dc.contributor.authorHo, PCen_HK
dc.date.accessioned2011-09-23T06:00:12Z-
dc.date.available2011-09-23T06:00:12Z-
dc.date.issued2011en_HK
dc.identifier.citationContraception, 2011, v. 83 n. 1, p. 62-67en_HK
dc.identifier.issn0010-7824en_HK
dc.identifier.urihttp://hdl.handle.net/10722/139909-
dc.description.abstractBackground: Letrozole is a third-generation selective aromatase inhibitor. Animal data suggested that it might be useful in medical abortion. We performed two pilot studies to assess the feasibility of using letrozole in combination with either mifepristone or misoprostol for termination of pregnancy up to 63 days. Study Design: We recruited 40 subjects who requested legal termination of pregnancies up to 63 days. Medical abortion was performed with letrozole 7.5 mg daily for 2 days followed by 800 mcg vaginal misoprostol in 20 subjects and letrozole 7.5 mg combined with 200 mg mifepristone in another 20 subjects. Results: The mean induction-to-abortion interval of the regimen of letrozole and misoprostol was 9.1 h (median 7.9 h, range 2.7-23.6 h). The complete abortion rate was 80% (95% CI: 56.3-94.3%). For those with gestation of ≤49 days, the complete abortion rate was 87.5% (14/16; 95% CI: 61.7-98.5%). The mean induction-to-abortion interval of letrozole combined with mifepristone was 90.1 h (median 93.4 h, range 66.0-121.2 h). The complete abortion rate was 71.4% (95% CI: 47.8-88.7%). Conclusion: These preliminary results suggest that a regimen of letrozole and misoprostol may be useful in medical abortion, but the combination with mifepristone is less effective and takes longer. Randomized studies comparing letrozole and misoprostol to misoprostol alone are warranted. © 2011 Elsevier Inc. All rights reserved.en_HK
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/contraceptionen_HK
dc.relation.ispartofContraceptionen_HK
dc.rightsNOTICE: this is the author’s version of a work that was accepted for publication in Contraception. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Contraception, 2011, v. 83 n. 1, p. 62-67. DOI:10.1016/j.contraception.2010.05.014-
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectFirst trimester medical abortionsen_HK
dc.subjectLetrozoleen_HK
dc.subjectMifepristoneen_HK
dc.subjectMisoprostolen_HK
dc.subject.meshAbortifacient Agents - administration and dosage-
dc.subject.meshAbortion, Induced - methods - standards-
dc.subject.meshMifepristone - administration and dosage-
dc.subject.meshMisoprostol - administration and dosage-
dc.subject.meshNitriles - administration and dosage-
dc.titleA pilot study on the use of letrozole with either misoprostol or mifepristone for termination of pregnancy up to 63 daysen_HK
dc.typeArticleen_HK
dc.identifier.emailNg, EHY:nghye@hkucc.hku.hken_HK
dc.identifier.emailYeung, WSB:wsbyeung@hkucc.hku.hken_HK
dc.identifier.emailHo, PC:pcho@hku.hken_HK
dc.identifier.authorityNg, EHY=rp00426en_HK
dc.identifier.authorityYeung, WSB=rp00331en_HK
dc.identifier.authorityHo, PC=rp00325en_HK
dc.description.naturepostprint-
dc.identifier.doi10.1016/j.contraception.2010.05.014en_HK
dc.identifier.pmid21134505-
dc.identifier.scopuseid_2-s2.0-78649906759en_HK
dc.identifier.hkuros196580en_US
dc.identifier.hkuros202233-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78649906759&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume83en_HK
dc.identifier.issue1en_HK
dc.identifier.spage62en_HK
dc.identifier.epage67en_HK
dc.identifier.isiWOS:000286088400010-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridLee, VCY=35758969300en_HK
dc.identifier.scopusauthoridTang, OS=39062295300en_HK
dc.identifier.scopusauthoridNg, EHY=35238184300en_HK
dc.identifier.scopusauthoridYeung, WSB=7102370745en_HK
dc.identifier.scopusauthoridHo, PC=7402211440en_HK
dc.identifier.citeulike7382065-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats